8-cyclooctylmethyl-1-(4-fluoro-phenyl)-3-(R)-(2-oxo-oxazolidin-5-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one | 1218940-80-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 8-cyclooctylmethyl-1-(4-fluoro-phenyl)-3-(R)-(2-oxo-oxazolidin-5-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one
• 英文别名: (5R)-5-[[8-(cyclooctylmethyl)-1-(4-fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]-1,3-oxazolidin-2-one
• CAS: 1218940-80-7
• 化学式: C₂₆H₃₇FN₄O₃
• 分子量: 472.603
• InChiKey: JYIPKURRKOCCOS-HSZRJFAPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  65.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-(3-amino-2-(R)-hydroxy-propyl)-8-cyclooctylmethyl-1-(4-fluorophenyl)-1,3,8-triaza-spiro[4.5]decan-4-one 、 三光气 在 sodium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 2.0h， 生成 8-cyclooctylmethyl-1-(4-fluoro-phenyl)-3-(R)-(2-oxo-oxazolidin-5-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one
  参考文献：
  名称：

  US2010/76003

  摘要：

  公开号：

文献信息

• 5-OXAZOLIDIN-2-ONE SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL AS ORL-1 RECEPTOR MODULATORS
  申请人：BATTISTA Kathleen

  公开号：US20100076003A1

  公开（公告）日：2010-03-25

  The present invention is directed to novel 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful in the treatment of disorders and conditions mediated by the ORL-1 receptor. The present invention is further directed to processes for the preparation of said derivatives, pharmaceutical compositions comprising said derivatives and methods for the treatment of ORL-1 mediated disorders and conditions.
• [EN] 5-OXAZOLIDIN-2-ONE SUBSTITUTED 1,3,8-TRIAZASPIRO [4.5] DECAN-4-ONE DERIVATIVES USEFUL AS ORL-1 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE 1,3,8-TRIAZASPIRO[4.5]DÉCAN-4-ONE SUBSTITUÉS PAR DE LA 5-OXAZOLIDIN-2-ONE UTILISABLES EN TANT QUE MODULATEURS DU RÉCEPTEUR ORL-1
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010033451A2

  公开（公告）日：2010-03-25

  The present invention is directed to novel 5-oxazolidin-2-one substituted 1,3,8-thazaspiro[4.5]decan-4-one derivatives useful in the treatment of disorders and conditions mediated by the ORL-1 receptor. The present invention is further directed to processes for the preparation of said derivatives, pharmaceutical compositions comprising said derivatives and methods for the treatment of ORL-1 mediated disorders and conditions.